SNMMI 2025

Implementing a shared Myocardial Perfusion Imaging (MPI) PET/CT program, healthcare institutions can position themselves at the forefront of advanced cardiac imaging while optimizing resource utilization. Previously, however, implementing a shared program was hindered by the availability of cardiac PET tracers requiring an on-site cyclotron or generator. The introduction of Flyrcado (flurpiridaz F 18) injection now provides accessibility of a unit dose cardiac PET tracer supplied from a local CMO allowing healthcare institutions to consider implementing a shared cardiac PET program without a large upfront financial commitment. This session will provide an overview of the practical considerations and clinical value of implementing a shared cardiac PET/CT MPI program with Flyrcado.

This session will cover the integration of advanced digital imaging techniques and AI-driven dosimetry, showcasing their impact on precision medicine. Gain insights into how these technologies are being used to improve diagnostic accuracy and therapeutic efficacy in Theranostics care.

This scientific symposium offers a cutting-edge perspective on the potential of innovative molecular imaging diagnostics across neurology, cardiology and oncology care areas, with a deeper dive into various oncological settings aimed at improving patient outcomes. Engage with leading experts in Nuclear Medicine and Oncology as they discuss the transformative role of novel PET radiotracers in redefining the future of cancer care through precision diagnostics. Speakers Paul Evans, PhD Head of Global R&D, Pharmaceutical Diagnostics, GE HealthCare Maheswari Senthil, MD, FACS Professor of Surgery, University of California Irvine, Orange, CA Andrew Scott, MBBS, MD, FRACP, FAHMS, FSNMMI Professor at Austin Health and Olivia Newton-John Cancer Research Institute, Melbourne (AUS) Ephraim Parent, MD, PhD Mayo Clinic Florida Department of Radiology, Jacksonville FL Pooja Advani, MBBS, MD Consultant and Breast Medical Oncologist, Mayo Clinic Comprehensive Cancer Center, Jacksonville FL Adam Schwarz, PhD Global Head of Imaging and Digital R&D, Pharmaceutical Diagnostics, GE HealthCare

Nearly 7 million Americans are living with Alzheimer’s disease. As the aging population grows and new therapies for Alzheimer’s Disease enter the market, amyloid PET imaging is an increasingly important tool for early and accurate diagnosis. GE HealthCare is pleased to provide an opportunity to learn more from Dr. Phillip Kuo about how Vizamyl’s advanced capabilities can support you in both typical and challenging patient cases. Upon completion of this session, you will be prepared to: • Interpret a Vizamyl PET image • Review a range of clinical case studies • Complete the Vizamyl reader training program assessment